Skip to content
‹ Back to IndustriesSciences

Terminator-Inspired Shape-Shifting Robot Becomes Reality. What Use Cases Does It Have in Manufacturing?

Thirty-two years after the release of Terminator 2, groundbreaking research in phase-shifting materials has made it possible for a real-life shape-shifting robot to exist. This new robot has the same ability as the T-1000 to transform into a liquid shape and pass through barriers. However, that’s where the similarities end. The new robot was…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By carey.scott · Liquid Metal RobotMagnetoactive Phase Transitional MatterManufacturingMptm
Share

Key takeaways

01

Thirty-two years after the release of Terminator 2, groundbreaking research in phase-shifting materials has made it possible for a real-life shape-shifting robot to exist.

02

This new robot has the same ability as the T-1000 to transform into a liquid shape and pass through barriers.

03

However, that’s where the similarities end.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI in a free MarketScale workspace. Qualifying companies also get one professional video edit a month. No credit card.

Try it Free

Thirty-two years after the release of Terminator 2, groundbreaking research in phase-shifting materials has made it possible for a real-life shape-shifting robot to exist. This new robot has the same ability as the T-1000 to transform into a liquid shape and pass through barriers. However, that’s where the similarities end.

The new robot was developed by a team from The Chinese University of Hong Kong under the direction of Dr. Chengfeng Pan. It is made up of a newly developed phase-shifting material researchers call “magnetoactive liquid-solid phase transitional matter,” or MPTM. Magnetic particles embedded in the material of the robot allow users to control it. This means it can be heated and cooled on demand using an alternating magnetic field to melt it into a liquid and then solidify it again.

This research is just one of the many advancements shaping the future of robotics and its use cases. Scientists are hoping that this discovery will one day be of use in a variety of fields, including medicine and assembly lines. MPTM could make it easier to solder and screw parts in hard-to-reach places, for example, but that’s hopefully just scratching the surface of its utility.

How can the manufacturing industry benefit from a shape-shifting robot? And are there any manufacturing applications where a flexible structure can make a huge difference? We reached out to Rhonda DiBachi, CEO of HeyScottie, for her expert opinion and analysis on this T-1000 tech. Rhonda has been implementing manufacturing techniques for companies since the 1980s and founded numerous startups for tech and manufacturing. 

Rhonda’s Thoughts:

“I don’t know of any manufacturing applications for this new material called MPTM or Magnetoactive Phase Transitional Matter. It’s early days. I do know of some applications of a similar kind of material called a shape memory alloy. That’s metals that change their shape depending upon changes in temperature and pressure.

I know that those are used in pneumatic and flow control systems to change valves. That’s interesting. An interesting application for this new kind of material, MPTM, I would think would be 3D printing, metal 3D printing. You could create struts using this material and when you’re building up the part you could use the struts, they would be structural.

But then when you’re done building up the part, you don’t need the struts anymore. And, if you could flip a switch and make them change their shape, they might be able to just slither out, making removal quite a bit easier than it is right now. Could be interesting.”

Article written by Sonia Gossai.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

C
carey.scott
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0. No credit card. Company confirmation required.

More Sciences Insights

CDMOs’ new capacity skews stainless by liters, but single-use leads by system count

CDMOs’ new capacity skews stainless by liters, but single-use leads by system count

Contract Pharma reports bioTRAK data projecting CDMOs will install roughly 120 bioreactors by 2030. It says 71% of added volume is large-scale stainless steel, while 61% of systems are single-use.

  • 01Utilization discipline is still driving builds: BioTRAK’s Dawn Ecker told Contract Pharma expansion conversations typically start after a site is booked above ~80% for several years.

Sep 22, 2026

Pharma supplier diversification means little if every supplier uses the same airport

Pharma supplier diversification means little if every supplier uses the same airport

Biocair's Patrick Wohl argues in Pharmaceutical Commerce that life sciences firms must map airports, sea lanes, customs gateways and carriers alongside suppliers. Suppliers spread across countries can still share one air hub. The fix he describes is pre-qualified alternate routes and continuous review, with clinical trial shipments and cold-chain medicines the first cargo exposed when a corridor closes.

  • 01A supplier base spread across several countries can still be a single point of failure if every shipment routes through one airport hub or corridor; the sharper question for a logistics provider is which hubs each qualified lane actually depends on.
  • 02Gartner data cited by MD+DI gives a benchmark: 42% of procurement leaders rank supply disruption as their organization's top risk, with geopolitical issues including tariffs and regulatory changes ranking third.
  • 03A route map ages fast. Pharmaceutical Commerce published the mapping argument on July 24 and was reporting fresh Red Sea and Iran-related freight risk for pharma lanes by Aug. 10, which is the case for treating mapping as a recurring review rather than a project.

Sep 17, 2026

Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply

Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply

Resilience and Eli Lilly are investing $750 million to expand KwikPen injectable device production at Resilience's Cincinnati-region manufacturing facility, expected to create 400 high-skilled jobs and reach full operations by early 2027. The partnership builds on their collaboration since 2023, which has already produced over 150 million doses of Lilly medications for the U.S. market.

  • 01$750 million investment to expand Resilience's Ohio manufacturing capacity for Eli Lilly's KwikPen injectable device production
  • 02400 new high-skilled jobs expected in Cincinnati region, with full operations by early 2027
  • 03Partnership has already produced over 150 million doses of Lilly medications for the U.S. market since 2023

Sep 14, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

C
carey.scott

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512